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Abstract
Objective: To document and explore the views and experiences of key stakeholders regarding the consent procedures of an
emergency research clinical trial examining immediate fluid resuscitation strategies, and to discuss the implications for
similar trials in future.
Methods: A social science sub-study of the FEAST (Fluid Expansion As Supportive Therapy) trial. Interviews were held with
trial team members (n = 30), health workers (n = 15) and parents (n = 51) from two purposively selected hospitals in Soroti,
Uganda, and Kilifi, Kenya.
Findings: Overall, deferred consent with prior assent was seen by staff and parents as having the potential to protect the
interests of both patients and researchers, and to avoid delays in starting treatment. An important challenge is that the
validity of verbal assent is undermined when inadequate initial information is poorly understood. This concern needs to be
balanced against the possibility that full prior consent on admission potentially causes harm through introducing delays.
Full prior consent also potentially imposes worries on parents that clinicians are uncertain about how to proceed and that
clinicians want to absolve themselves of any responsibility for the child’s outcome (some parents’ interpretation of the need
for signed consent). Voluntariness is clearly compromised for both verbal assent and full prior consent in a context of such
vulnerability and stress. Further challenges in obtaining verbal assent were: what to do in the absence of the household
decision-maker (often the father); and how medical staff handle parents not giving a clear agreement or refusal.
Conclusion: While the challenges identified are faced in all research in low-income settings, they are magnified for
emergency trials by the urgency of decision making and treatment needs. Consent options will need to be tailored to
particular studies and settings, and might best be informed by consultation with staff members and community
representatives using a deliberative approach.
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Introduction
Alternatives to Full Prior Consent in Emergency Research
Emergency research involves people with a life-threatening
medical condition that requires urgent intervention, and emer-
gency trials are important to allow relevant interventions to be
evaluated. Given that most interventions used in the treatment and
management of critically ill children have at best only been tested
in animals or in adults, there is a need for emergency paediatric
trials to advance evidence-based paediatric practice, and child
health and well-being [1].
In emergency paediatric research, prior consent by parents or
other legal guardians is recommended by the EU, but is
recognised as challenging given the urgency of the patient’s
condition, and the difficulty for the guardian of assimilating trial
information in such distressing circumstances [1,2]. Current
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regulations in some European countries and in the United States
allow for alternatives to full prior individual consent in emergency
research, while guidelines elsewhere in the world vary or are not
specifically addressed [3]. The FDA allows for alternatives to full
prior individual consent only in specific situations, as follows [4]:
– The subject has a life threatening condition that necessitates
urgent intervention;
– Available treatments are unproven or satisfactory;
– Consent from the subject (or a surrogate) is not feasible due to
the urgency of the patient/subject’s condition;
– The research could not otherwise be performed;
– The risks and benefits are reasonable;
– There is a prospect that the trial will be of direct medical
benefit to the patient/subject; and
– There is consultation with the community from which subjects
will be drawn, including public disclosure of the study design
and risks prior to commencement.
These conditions have been argued to be unnecessarily
restrictive, and to have contributed to a decline in the amount
of emergency research.
A range of alternatives to full prior individual consent have been
suggested, with deferred consent distinguished here from retro-
spective assent through including prior assent. Assent refers to an
affirmative agreement; an agreement which implies at least a
minimal level of understanding and ability to indicate a choice
(Table 1; drawing on [1,5,6,7]). Each alternative option has its
limitations. While there is no consensus on the most appropriate
approach, it is generally agreed that full information must be given
to surrogates as soon as possible, and that guidelines and
regulations that apply to all clinical studies must be adhered to
[8,9], including having a Data Safety and Monitoring Board.
Ideally, emergency research should also be reviewed by commit-
tees with special training [1,10].
Given the challenges in obtaining full prior consent in paediatric
emergency research, and variability and controversy in current
guidelines and regulations [3], documentation and exploration of
alternative approaches to obtaining informed consent in emer-
gency research involving children is needed. We therefore
conducted a social science sub-study alongside an emergency
paediatric care trial to document and explore the views and
experiences of key stakeholders – trial team members, health
workers and parents - regarding the consent procedures.
The Consent Process in the FEAST Trial
The FEAST (Fluid Expansion As Supportive Therapy) trial was
an emergency paediatric trial aimed at identifying the best
strategies for treating and managing critically sick children on
admission to hospital with severe febrile illness and shock. The trial
was conducted in six hospitals in three East African countries
(Uganda, Tanzania and Kenya), and involved 3170 critically ill
children – with an estimated mortality rate of 15% - aged between
2 months and 12 years. The trial was a 3-arm randomised open
comparative trial of fluid resuscitation strategies with children
randomised into: (1) Immediate volume resuscitation with normal
(0.9%) saline; (2) immediate volume expansion with 5% human
albumin solution (HAS); or (3) control: no immediate volume
expansion. The trial has been described in detail elsewhere [11].
The trial team and colleagues drew upon existing guidance and
commentaries to develop a consent process which included written
prior consent where possible, but an option for deferred consent
with prior assent for a sub-set of children who needed immediate
resuscitation (where prior consent was not possible), or where
guardians or parents were not available or were perceived to be so
distressed they were unable to receive or understand information
(Table 2).
In the FEAST trial, therefore, deferred consent involved a
verbal assent from parents or guardians prior to enrolment (see
Table 3 for information included) and a delayed full informed
written consent after the child had stabilised and when it was
perceived that parents were better able to receive, evaluate and
discuss the information. The intention was that verbal assent
allowed parents to make a decision about trial participation on the
basis of brief information, and gave them an opportunity to ‘opt
out’. For the children who died shortly after verbal assent on
admission, and before full consent, parents were not approached
for retrospective informed consent. As elsewhere [2,12,13],
obtaining consent from bereaved parents was considered to
potentially further distress parents at a profoundly emotional
Table 1. Alternatives to prior individual consent in emergency paediatric research.
Type of consent Characteristics Critique
Deferred consent Initial assent to enter the study is obtained
Full informed consent is deferred (delayed) until the patient
has stabilised and/or surrogates are
able to listen and understand trial information
Surrogates can withdraw at any point
Consent cannot be obtained after the intervention has already been
given; consent is only therefore permission to remain in the study
Proxy consent by
third parties
An appropriate person other than the parent/immediate guardian
gives consent for the participant
Potential proxies include - legal representatives, and independent
physicians
Difficulties in ensuring independence of proxies
Proxies not capable of knowing the wishes of a parent especially
without prior discussion
Advanced consent/
Presumed consent:
Potential participants are identified prior to meeting eligibility
criteria and consent for future enrolment should they
became eligible
Difficult to identify participants in advance in emergency research
Potentially causes unnecessary distress or harm, especially where
inclusion criteria are not met
Retrospective
consent
Initial research intervention occurs without the surrogate’s consent
Consenting takes place after the initiation or completion of
the research intervention
Participants have no control over what has been done in the past
Waiver of consent: Research intervention occurs without the participant’s or
surrogate’s consent
Considered to be a violation of patient autonomy
doi:10.1371/journal.pone.0054894.t001
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time, possibly resulting in parents blaming themselves for
permitting research participation [3].
An intensive training and retraining process was conducted for
the FEAST trial by trained facilitators, including specific modules
on assent and consent. Interactive training methods drew upon
trainees’ knowledge and experience to contribute ideas for
handling potential field scenarios, within an institutionally agreed
consent SOP [14]. The time required for verbal assent was
generally 2–5 minutes and could be obtained at the bedside, even
whilst other aspects of emergency care were being administered
(e.g. airway, oxygen, hypoglycemia correction). Consent required
the full attention of the parent or guardian and generally took 20–
30 minutes depending upon the amount of discussion. The latest
international guidelines [15] recommend rapid and prompt fluid
resuscitation of shock within 15 minutes of diagnosis, and the
WHO guidelines recommend treatment ‘as quickly as possible’
[16], illustrating the importance of the deferred consent option for
some parents (Table 2). Consent processes were reviewed regularly
by monitors, and staff were encouraged to raise any challenges in
day to day trial administration to their line managers or to the
trainers throughout the trial. As part of community engagement,
trial specific information was shared with key communities before
the trial began, with key communities defined as ward parents, and
hospital ward staff and managers. Widespread information giving
in communities was opted against given the large size of hospital
catchment areas, the small proportion of children who would
ultimately be eligible for the trial, and the potential for complex
information given in large community meetings to cause
unnecessary concerns about attending hospitals for care.
In this paper we present the findings of the social science sub-
study of the FEAST trial, and consider the implications for similar
trials in such settings in future. We do not seek to evaluate or
discuss the ethics of the trial, which was approved by science and
ethics committees in four countries (UK, Uganda, Kenya, and
Tanzania).
Methods
Study Sites – two FEAST Trial Hospitals
The consent study was conducted in two FEAST trial sites:
Kilifi District Hospital (KDH), Kenya and Soroti Regional
Referral Hospital (SRRH), Uganda. The sites were purposively
selected to offer differing experiences based on different back-
ground situations, levels and types of trial inputs into the site
(Table 4), and therefore perceived individual benefits.
Consent Sub Study Data Collection and Analysis
We held interviews with parents and trial staff and health
workers between June and December 2010, before the trial was
stopped early in January 2011 by the Independent Data and
Safety Monitoring committee because of lack of benefit and
potential harm from bolus fluid in African hospitals compared to
control [11].
Interviews with parents. 34 in-depth interviews were held
with parents of participating children (15 in Kilifi; 19 in Soroti);
and five with parents who had refused (all in Kilifi). In addition, we
interviewed 12 parents of children concurrently admitted in the
wards but not involved with the trial in Soroti. The equivalent
figure for Kilifi was 138; a higher figure because these interviews
were being conducted as part of a broader study. Trial participants
were identified from trial data, and other parents on discharge
from the wards. Inclusion of non-study parents was aimed at
identifying whether issues raised by trial participant parents were
more about high dependency ward experiences than the trial itself.
Parents of children who had died were not included due to the
very sensitive nature of such interviews. Interviews with parents
were conducted in parents’ preferred language, by trained staff.
Interviews with trial staff and health workers. We
interviewed 30 staff involved with the FEAST trial (15 in Soroti
and 9 in Kilifi) individually, and held two group discussions with
health workers (primarily nurses) in Kilifi (N= 15). Six additional
individual interviews were held with hospital staff and managers.
All staff interviews were conducted in English by SM and MN.
Table 2. Criteria for deferred consent in FEAST Study [3].
Degree of Emergency Consent Status
Pre-terminal Deferred consent
Immediate resuscitation: other life threatening complications e.g. seizures, hypoglycaemia, hypoxia Deferred consent
No other life threatening complications: parents able to receive and understand information Full informed consent prior to enrolment
No other life threatening complications: Guardian or parent not available or; parent or guardian unable
to receive or understand information
Deferred consent
doi:10.1371/journal.pone.0054894.t002
Table 3. Phrasing of assent in the deferred consent process [3].
We are going to provide the treatment for your child that is recommended by the government.
We want to find out if we can improve on these current recommendations by trying new treatments that we think will work better. We do this by research
All research is checked by independent committees to make sure that the potential benefits to individuals outweigh the risks. All participation in research is voluntary,
and so you can refuse
We would like your child to participate in research for us to learn the best way to give fluids to very sick children.
Do you agree for your child to take part in this research? You can say no and your child will still receive the same level of care with the governments recommended
treatment.
doi:10.1371/journal.pone.0054894.t003
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All interviews were recorded, transcribed, and - where relevant -
translated. Data were analysed using a modified framework
approach [17]. Data were imported into NVIVO 9, and organised
using a coding tree developed by SM and MN based on pre-study
areas of interest and independent reviews of a sub-set of
transcriptions. Charts by theme allowed comparison of issues
identified by site and type of interviewee.
Ethics Statement
The consent sub-study of the FEAST trial was approved by
National Ethics Review committees in Kenya and Uganda (the
Kenya Medical Research Institute Ethics Review Committee and
the Makerere University Faculty of Medical Research and Ethics
Committee respectively). Written consent was sought from all
respondents. Interviews were conducted independently of the trial
team, led by researchers with a long interest in consent processes
in East Africa [18,19,20]. All recordings, transcriptions and quotes
have been anonymised to protect confidentiality.
Findings
Following an overview of the consent rates and types across the
two sites, we present staff and then parent perceptions of the
consent process, followed by two factors influencing perceptions:
parental understanding and decision-making in the trial, and
factors influencing this.
Rates and Types of Consent in the Study Sites
Information on consent rates and type was collected as part of
the trial procedures (Table 5).
Across all six trial sites, 49% of parents gave full prior consent
and 47% assent prior to randomisation as part of a deferred
consent process. A small proportion (4%) only gave assent, with
these patients dying before deferred consent could be sought. Only
a tiny fraction (0.4%) of parents who initially assented or
consented to participation in the trial later withdrew their
children.
The number of children enrolled in the trial was higher in
Soroti (n = 633; contributing 20% of total trial participants) than
Kilifi (n = 216; contributing 6.8%). We found substantial and
statistically significant differences between Kilifi and Soroti in rates
of consent and in the proportion with prior assent. 87% of
participants’ parents in Kilifi gave prior full consent (189/216);
whereas in Soroti the equivalent proportion was 40% (257/633)
(chi-squared p,0.0001). Just over half of parents in Soroti (54%)
and 11% in Kilifi (p,0.0001) went through the prior assent with
deferred consent. In Kilifi, a far higher proportion of screened and
eligible participants refused consent (36%; 123/339) compared to
Soroti (4%; 27/660) (p,0.0001).
Staff Perceptions of the Consent Process
Positive views. The approach to consent developed by the
trial team was generally strongly supported by all staff, with some
nurses in Kilifi describing the consenting process as fostering
rapport, trust and communication with patients. It was felt to be
important to have prior full consent wherever possible to avoid
‘depriving the mother of the full information that she needs to make an informed
decision’. Including assent for the critically ill, as opposed to a
waiver or retrospective consent, was felt to be important because
the research involved an intervention (fluid boluses) that was not
Table 4. Key features of the two FEAST trial sites.
Site Kilifi District Hospital (KDH), Kenya Soroti Regional Referral Hospital (SRRH), Uganda
Size of paediatric wards 42 beds 62 beds
Experience conducting trials Clinical trials conducted for over 20 years First major research activity
Community engagement
activities
Coordinated community engagement activities focusing on
the institution and (where appropriate) specific studies
No formalised community engagement strategies for research
Employment and training
of staff
Most staff within pre-existing clinical research group Most staff involved in the trial trained and recruited specifically
Refusal rates for trial High relative to other sites Low relative particularly to KDH
Hospital user charges and
other costs (a)
National exemption of charges for under five year olds, but little
policy adherence.
Food is provided for patients and most basic consumables
available at a cost.
National exemption of charges for all admissions, but little policy
adherence.
Relatives provide and cook food in hospital grounds, and purchase
many consumables needed (e.g. gloves, intravenous lines, some
medicines) from local shops.
Trial inputs into study site Established clinical programme as a robust platform for
clinical trials (b). Also, trial provided extra personnel for
emergency triage and patient monitoring, additional
diagnostic tests and service-wide training in
emergency care.
Basic maintenance and painting of paediatric wards, emergency
and triage equipment and training for all staff, and employment
of additional personnel.
Trial benefits for
individuals (d)
Close observation, treatment of new illnesses identified during
admission, and free treatment of minor illnesses post discharge up
until the 28-day follow-up visit.
As with KDH, every trial participant was allocated a dedicated
‘clinical trial pack’(c).
(a) See [32,33] for information on lack of adherence to user fee policies.
(b) Includes substantial support to the hospital for medical personnel (doctors, clinical officers, nurses and ward assistants); paediatric drugs, devices and equipment.
Research funds also support the construction and running of an 8-bed paediatric high dependency ward available to all paediatric admissions, regardless of research
involvement.
(c) Including cannulae, syringes, infusion sets, antibiotics, anti-malarials and blood testing consumables. Not needed in KDH where such support is provided to all
inpatients in HDU.
(d) The usual hospital admission fees for the participants were not waived during the trial, in an effort to ensure that parents did not feel obliged to join the trial to save
money. However, in Soroti only a few patients in a semi-private room are charged fees by the hospital.
doi:10.1371/journal.pone.0054894.t004
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standard of care, and therefore some information and an ability to
opt out for parents was required:
I think we should [assent] because this is not standard treatment that
you are giving; you are doing research and you don’t know for sure
whether what you are giving is good or whether it’s bad…(Soroti\S-
taff\ST011).
Most staff involved in administering a deferred consent process
with verbal assent were administering this form of consent for the
first time and viewed it very positively. They appreciated that it
allowed emergency treatments to be started without delay:
I felt that the hastened bit of it [referring to assent] was quite
appropriate… because when the patient is that sick you also feel for the
patient and you feel for that mother. [You think] ‘What if something
happens before I start these fluids while maybe I am talking to this
mother?’ (Kilifi\Staff\KL011).
Also regularly mentioned by staff was that including an option
for verbal assent allowed them to continue with the research in a
way that protected them from any later blame from parents for
having enrolled children:
There are people who are really difficult. When you start doing
something on the child and the child dies, then there you will be stuck:
somebody can start saying that had it not been because of these [study
procedures], my child would not have died…. (Soroti\Staff\ST012).
We have to tell them whatever is happening because if you don’t tell
them and something happens, the blame will be on us (Kilifi\S-
taff\KL005).
Deferred consent (following initial verbal assent) was also
described as ensuring that another formal step to support parents’
understanding and their ability to withdraw was introduced:
You know even you if you are in a state of shock (laughing) you may say
yes to something if you are not mentally stable… you may say yes then
later you say no when you came to that part of filling in the consent
form… at that point it will be wise for you to withdraw that child from
the study and it’s really understandable… it is very important to go back
as soon as possible (Soroti\Staff\ST009).
A final argument often raised in favour of deferred consent was
that it can allow some ‘buying of time’ to wait for key decision
makers to arrive when children are brought to hospital by relatives
other than their parents, or by a mother who does not want to
make a definitive decision on her husbands’ behalf:
…depending on families there are mothers who can make decisions by
themselves so those ones can accept, but there are these ones who rely on
the father as the one to make decisions - majority of them go for the
assent (Soroti\Staff\ST012).
This latter point was challenged by some interviewees,
particularly in Kilifi, where there was some lack of clarity on
whether or not there was a study-specific ‘arrangement’ to allow
research to proceed in these circumstances. Some Kilifi-based
interviewees were concerned that this would not be permitted in
ethical practice more globally, and about how the child’s parents
might later react if they heard their child had been assented by
somebody else:
When it comes to relatives assenting or consenting for patients who are
not their children it’s a bit tricky and because this child is not theirs…
you never know how the parents will react, so I think an assent
cannot…[be] for somebody who is not present (Kilifi\Staff\KL011).
Challenges and concerns shared by staff. The main
challenge raised by staff was the validity of either assent or full
consent when given by guardians during admission of a critically
sick child:
Remember you are getting somebody in a very desperate situation and
you are saying, okay I have screened this patient, and this patient is
eligible now we have such and such a trial but at this stage I just need
you to tell me whether you are willing or not willing to participate. Now
to somebody who is desperate I think a yes answer is bigger than a no
answer…the desperation here is not … to enter the trial but somebody is
desperate to save the life of a very critically sick person
(Soroti\Staff\MB001).
The above quote hints at parents feeling like they have to agree
to ensure their children receive all emergency treatment rather
than the study intervention. Other challenges highlighted by staff
were parents not being able to listen given their anxiety, and –
overlapping with both perceived pressure to agree and with
difficulties in concentrating and understanding the information –
parents believing that by agreeing to trial enrolment that all
children would receive a fluid bolus (as opposed to no-bolus, the
Table 5. FEAST trial consent rates and types of consent.
Type of consent Overall Kilifi Soroti
Total Enrolled 3170 216 633
Assent Only (% of enrolled) 135 (4%) 4 (2%) 36 (6%)
Full prior consent (% of enrolled) 1534 (49%) 189 (87%) 257 (40%)
Deferred consent following assent (% of enrolled) 1501 (47%) 23 (11%) 340 (54%)
Total eligible* 3463 339 660
Refused consent (% of eligible) 293 (8.5%) 123 (36%) 27 (4%)
*Not including those that met inclusion criteria but were not enrolled for other reasons such as trial packs not being available. Refer to FEAST Trial paper for more
information on ‘other’ reasons for non-enrolment.
doi:10.1371/journal.pone.0054894.t005
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control). The bolus was reportedly seen as primarily to benefit
their child.
A potential risk regarding deferred consent raised more often in
Soroti than in Kilifi was that the option could be overused;
introducing ‘a laziness’ in staff. In Kilifi, some staff argued that
assent could ultimately lead to more late refusals, with parents
having less interest in continuing to be in the study and
withdrawing permission once their child had begun to improve
(the point at which full consent is sought). This was difficult to
explore quantitatively, given the small numbers with deferred
consent in Kilifi.
In both settings staff reported that even the assent process
introduces delays through encouraging questions, which introduc-
es a dilemma in delaying initiation of treatment. Apparently
unclear among staff was exactly what information they should give
during assent. Although SOPs include the information, and this
was covered during training, some staff reported that what to say
was ‘really much more left to the prerogative of the clinician or the nurse’.
Some staff were also unclear about whether or not an actual ‘yes’
was required; reportedly a major challenge in both settings where
mothers often told staff to ‘just do what you want’:
These mothers come with all their anxiety, the child is sick. As much as
someone would try to look brave and to say that I have actually
understood go ahead - … mostly they say ‘do what you can, what I
want to see is my child well’ (Kilifi\Staff\KL011).
The challenge was whether to accept such comments as a form
of implicit agreement. Also unclear to staff was how to handle
mothers who want to wait for a father to decide on study
participation. In both settings fathers are often the main decision-
makers in households but may not be present when the child is
admitted. The dilemma is whether or not the mother is using the
husband as a way to politely refuse; as a form of ‘silent refusal’:
It’s quite hard because often the reason you are given is that maybe ‘huyu
ni mtoto wa wenyewe’ [this is the owner’s - i.e. the father’s - child]….,
‘I need the father also to give consent’ or that ‘I am waiting for the
father’. So often they will not really come out and tell you that it is
KEMRI [that is worrying me] but they always give other reasons
(Kilifi\Staff\KL008).
One Kilifi staff member described asking the mother if she
herself felt comfortable with the trial, and if so, suggesting that the
child was enrolled and that the husband be fully informed on
arrival. Because when fathers do later come, they ‘are usually not
problematic so it’s just the fear the mothers have but the fathers are usually quite
positive, quite ok to accept’. However some parents’ comments
illustrate the potentially serious consequences of going against a
father’s wishes:
you don’t know how they are living at their home………that [ie a
woman deciding in the absence of a husband] may cause her to be
slapped (laughs)… because the husband may want to know why she
has done that; why she didn’t wait for her husband to come…. That
may cause chaos (Kilifi/Parent/KLF 004).
The provision in the FEAST trial to waiver full consent if a child
died following enrolment by parental assent, was understood and
supported by most staff. They commented that it would ‘not be
good’ or be ‘unethical’ to go back, given the sensitivity of the
situation. Parents are typically crying, and sometimes collapsing.
However, one staff member thought it was a study requirement to
retrospectively obtain full consent even in the event of a death.
Several felt that although it would be ‘harsh because someone has just
lost their child and they are emotionally upset and all that’; it would have
been better to obtain consent retrospectively to protect staff legally.
Parents’ Recall and Perceptions of the Informed Consent
Process
As might be expected from staff comments and the medical
condition of many children, parents’ descriptions of the admission
process and information given at that stage focused on their
concern for the child’s health and for their desire for treatment to
proceed as fast as possible. Many parents said they ‘cannot
remember’ or ‘have forgotten’ what they were told, or that they
were ‘not listening to anything’. As one mother described in
Soroti:
You know, you can also forget because the things [they told me] were too
many and you know being only one head my heart was shaken about
how the child was…that’s why [my head] didn’t grab many things
(Soroti/FEAST mother/ST 010).
Others had some recollection, sometimes quite detailed, of the
consent process and of the content of the discussion, but even these
relatively detailed descriptions illustrate some lack of understand-
ing or recall of the relevant trial details, and a hope or belief that
inclusion in the trial is positive for the child. Two examples:
It’s a person’s freewill. If you agree to join that group, something like
that, that’s when your child will be put some water but if you refuse,
your child will not. That’s why she asked me before they put the water
in the child and asked me whether I agree or not but I considered my
child’s condition and said it’s alright. But the water is really
helpful to the child. (Kilifi/Parent/KLF 011; authors’
emphasis).
They said that they are working with Makerere University and they
have come to bring a study that involves treating people using fluids or
something like that. They told me that it’s not only here, it is also being
done in other places and countries including even some countries in
Africa and others outside Africa. They are trying to treat children who
are very ill using fluids. They also said that the way they have seen in
some countries, it seems it is good so they also want to try it in Uganda
to check if it is good so that they can see whether to continue that kind of
treatment. Then they asked me that do you accept to be with us in this
study? That they would treat the child and at the same time studying if I
agreed. So I said that I agree, then they started treating the child from
that day up to today, the child is still in their hands (Soroti/
FEAST Father/ST 011; authors’ emphasis).
Many parents appreciated having been given some information
before treatment began, but some felt – sometimes quite strongly -
that it was pointless or even an additional worry to be given
information and especially being asked ‘opinions’ (i.e. consent) at
the stage:
Understanding, [is not something that can happen] until somebody sees
her child is fine or recovered, but if you came to me and announce or
talk, shouting to me explaining to me about KEMRI when my child is
ailing... I won’t listen to you, it’s like you will be
talking to the wind and the words will pass with the
blowing wind. Because to me I will be looking on the condition of
Views on Deferred Consent in Emergency Research
PLOS ONE | www.plosone.org 6 February 2013 | Volume 8 | Issue 2 | e54894
my child; not listening to you (Kilifi/Parent/KLF 016; authors’
emphasis).
What was not appropriate or what didn’t please me was that of being
consulted first … I felt bad because you have come all the way from
home because your child is not feeling well, you have brought the child
and instead of them taking an urgent step of treating
the child they start asking for your advice…. If it were
not my decision I wouldn’t have brought the child to this place…
(Kilifi/Parent/KLF007; author’s emphasis).
Another mother’s comment suggested that the way that consent
was administered may not always have been ideal:
I was seated but my child was on a bed somewhere aside… she was
even explaining while I had stood up to look at my child. In the end she
[the nurse] asked them [the other nurses] to block me from seeing my
child [so I would listen]. I cannot complain because they were in a
hurry so as for the child to be put [on] the [infusion of] water (Kilifi/
Parent/KLF 011).
In Kilifi, some of those who refused suggested that the consent
signature indicated a handing over of the child; an absolution of
blame on all sides ‘like if anything happens I don’t want us to blame each
other’ which was felt to be deeply uncomfortable given the severity
of the child’s illness:
You are told it is your decision. That is what is making people refuse
because instead of just treating the child so that he/she is cured … It’s
like you are saying in case there is anything that happens, I don’t want
us to blame each other. Because you will have signed and you won’t have
anything to say because you have signed yourself. So that is why people
are refusing (Kilifi/Parent/KLF007).
The overwhelming recommendation from parents was for the
treatment to come first and the talking and explaining later:
When a child arrives there, let him/her be treated first and then later let
[the parents] be asked the questions. I even told the nurses that but they
said if you have not yet decided ‘yes’ or ‘no’, we can’t start giving the
child water. Now, because I want the child to recover I have to say ‘yes’
so that they can start the water (Kilifi/Parent/KLF 013).
Factors Influencing Parental Decision-making
Many of the above comments, including from staff, illustrate the
difficulty of differentiating a trial related treatment intervention
from standard of care. Looking across all parents’ responses to
questions during our interviews, only 7/39 (18%) appeared to
recall the nature of the research they were involved in, 23/39
(59%) recollected some elements of the research, and 9 (23%)
simply described their whole experience as clinical care (Table 6).
Those with good or some recall described a ‘project’, voluntary
participation, and non-routine ‘water’ treatment. For some, simply
being asked (i.e. consent) triggered their knowledge that they were
in a research project.
Clearly difficult for parents and staff was explaining and
understanding the concept of a trial and ‘equipoise’, leading to
many parents suggesting that a decision, and particularly saying
‘no’, did not make any sense:
If you refuse what will you do in that condition and I have
followed you, you cannot refuse. If I were to refuse, I
couldn’t have come with him to the hospital (pause) we are grateful.
(Kilifi/Parent/KLF 011; authors’ emphasis).
The above perception may have been contributed to by many
of the trial staff apparently not being in equipoise at the time of
this consent sub-study, with many believing that the intervention
arms would prove to be life saving. As one staff member reported:
we have come to appreciate that at least that rapid infusion of fluids
within the first one hour for very sick children really has some benefits so
we are even trying to do it informally not only for the FEAST children
but for some other children… it has helped us at least come to that
conclusion even before the study has concluded (Soroti\Staff\ST009).
Others were concerned that refusal might lead to poorer quality
of care, with one parent in Soroti mentioning you would have to
‘go to the other side where you have to buy things’. This might relate to the
FEAST patients being relatively distinguishable from others in the
ward not participating in the trial in Soroti due to their physical
location and also because enrolled children did not have to buy
prescribed medicines or infusion lines as often happens for
paediatric patients (see Table 4). This difference contributed to
trial participants being perceived by parents as getting much better
quality of care.
Once you are in that room [study room] you are given everything even the
cannula, quinine, the drugs…All you do is to just look and appreciate
that the child is being treated. The only expenditure is on what you have
to eat and for the child because you see that even life is getting better …
Even the nurses are good and the help offered is okay (Soroti/Non-
FEAST mother/ST 005).
you can wish in your heart that if only you were also the one being
treated like that, maybe it would be better (Soroti/Non-FEAST
Mother/ST 001).
Certainly, in both settings, participants’ parents greatly appre-
ciated the close monitoring and quick attention given to their
children while at the ward, and regularly discussed being
impressed and pleased by the concern and ‘tender care’ shown
to children by the nurses and doctors.
Parents’ relatively low exposure to science and research was
often mentioned by staff as contributing to parents’ inability to
differentiate between research and standard care. In Kilifi,
previous information about or personal experience with research
studies in the wards or in the community sometimes led to parents
automatically refusing the trial, either because they were aware
that research participation is voluntary and had no interest in
participating, or through a general concern about the institution’s
research. The latter was sometimes based on rumours that have
been extensively described in Kilifi and elsewhere [18,20],
including misperceptions that blood samples are mixed and sold,
or that staff are ‘devil-worshippers’. In other cases, past experience
or information about KEMRI was much more positive, and
appeared to lead to an automatic yes, regardless of understanding
of study details:
I told him that I know KEMRI; one of my grandchildren is in a
KEMRI malaria vaccine study so I know this organisation. When he
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asked me whether I was going to join or not I told him that I’m happy to
and I joined (Kilifi/Parent/KLF017).
Discussion
There is widespread agreement on the need for emergency
paediatric research, arguably particularly in low-income settings
such as sub-Saharan Africa where a disproportionate burden of
child mortality occurs within hospitals, often within hours of
admission. An important challenge with regards to such trials is
developing an appropriate consent process. The interviews we
held with those most closely involved with the FEAST trial reveal
the significant challenges faced in meeting all of the key elements
of consent: parents are seriously anxious and vulnerable; and staff
are stressed by balancing the urgent need to proceed with
treatment with a concern about being later blamed by parents for
encouraging them to join a trial without meaningful initial
consultation. This latter point is important given staff recognition
of the potentially pivotal role they play in handling a high-risk
group of children.
Differences in Consent Types by Site, and Views of the
FEAST Consent Approach
Contextual differences between Kilifi and Soroti potentially
contributed to less deferred consent and more refusals in Kilifi
(Table 5). Contextual differences include those laid out in Table 4,
as well as children being perceived by staff as generally less
severely ill in Kilifi (and therefore less likely to be eligible for
deferred consent), other studies actively recruiting children at the
time when FEAST was being conducted in Kilifi (impacting on
both staff pressure and parent interest), staff being more familiar
with and therefore comfortable with full prior consent in Kilifi,
and possibly generally more male decision-makers being present in
Soroti.
Overall, the consent approach adopted by the trial, with an
option for verbal assent with deferred full consent was seen in both
settings as potentially protecting the interests of both patients and
researchers where full prior consent was difficult or impossible.
This option was also appreciated for avoiding delays in starting
treatment. Other benefits were described as the formal introduc-
tion of a two stage process supporting better understanding,
allowing another opportunity for parents to withdraw, and
allowing other relatives to be involved in the consent process.
Important to note however is that these latter benefits could
potentially also be incorporated into a full prior consent process.
Within a generally positive view of the consent process,
particularly among staff members, there were also some serious
concerns raised. A major issue - revealed through discussions
primarily with parents - was that being asked to make choices and
listen to information on admission potentially causes harm,
through raising concerns and doubts at a time when parents are
unable to listen, ask, understand, or challenge those they are
seeking help from. Relatedly, is whether voluntary decisions can
ever really be made in this emergency context.
Alternatives to the FEAST Trial Approach to Consent and
Areas Needing Further Deliberation and Resolution
The main suggestion or recommendation from parents was that
researchers should ‘just get on with treating their child’, and worry
about consent later. This suggestion from parents in our settings
echoes views of parents in UK gathered through a postal
questionnaire survey aimed at informing a proposed double blind
RCT [13]. However, some aspects of our data suggest caution in
retrospective consent for all (Table 1):
N From a moral perspective, parents have a right to make a
choice on their own terms [1], because the expert does not
know everything and cannot know what is best for each person
in a medical trial. Some parents did refuse, particularly in
Kilifi, suggesting that prior assent or consent does give some
people a choice, and interviews with refusals did not suggest
that parents regretted this refusal;
N Some parents appreciated being given some information and
an opportunity to opt out, despite recognising the difficulties in
understanding;
N Most staff felt that it would be inappropriate not to give parents
any choice prior to starting the study, for both moral and –
possibly more strongly - legal reasons;
N Parents who recommended mandatory retrospective consent
did not always appear to have a full understanding that their
child had been involved in a trial. Parents’ recommendations
may have differed significantly if they had understood their
children had been involved in a trial, and the implications of
this, more fully.
N Over time, there is a possibility that in a context of some
concerns about, and distrust in research, an awareness that
children could be enrolled without any prior information or
option to opt out, could undermine public trust in health
services and in researchers.
N We did not interview a key group of parents; those whose
children had died, whose views - if based on an understanding
of the trial and its implications – may have differed
significantly.
An alternative to retrospective consent would be to implement
deferred consent with a prior assent for all. Parents’ descriptions suggest
that regardless of the severity of the illness in clinical terms, a child
entering into an HDU with an acute illness leads to such anxiety
that all parents effectively meet the criteria for deferred consent
with prior assent. If the assent process information included a clear
option for full consent at the point of admission if parents wanted
it, the parent would then have greater control themselves on the
amount of information they received on admission, rather than
leaving it to staff to assess suitability based on a predefined criteria,
Table 6. Parents’ recall on discharge that their children were in a study.
Levels of Understanding Kilifi (n = 19) Soroti (n = 20) Total (n = 39)
Clear understanding 3 4 7
Some elements of trial understood 13 10 23
No apparent distinction from clinical care 3 6 9
doi:10.1371/journal.pone.0054894.t006
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or staff making the subjective decision about levels of ‘parental
distress’.
A challenge with the latter is staff members’ preference
particularly in Kilifi for a one-step full consent process in advance
in order to comply with all the legal requirements of research
inclusion in one go. However full consent at enrolment is unlikely
to meet the moral commitment to individual choice even if
fulfilling the legal commitment [21]. This preference may also
have in part been related to some lack of clarity among staff that
the national ethics committee which approved the trial has been
accredited by the Pharmacy and Poison’s Board (PPB) and the
National Council for Science & Technology (NCST); and that the
PPB and NCST have in turn been delegated the authority
nationally to regulate clinical trials. The two-step prior assent
followed by full later consent process for all, or possibly even a
more continuous consent process [22], with an option for parents
to choose full prior consent, potentially allows both the moral and
legal approaches to consent to be met. An important problem is
that the confusions, anxieties and delays introduced by parents
being presented with and facing a choice on admission are not
avoided.
Given the challenges with each option raised above, future
similar studies would potentially benefit from more prior
community consultation on the above options, and on further
more specific issues raised by this study, as discussed below:
What to do in the absence of the father, or both
parents. Consenting non-parents has been practised by others,
where circumstances for deferred consent have included ‘physical
absence of the patient’s relative [in such a circumstance]… as soon
as relatives arrive, this circumstance is no longer valid, and hence
consent should immediately be sought’ (Jansen, p 897). We found
that ‘buying time’ does not necessarily build confidence in a moral
commitment to the goals of consent processes, as opposed to a
determination to achieve the study sample sizes.
Literature from this part of the world and our data suggest that
there might be serious harms from proceeding with a trial in the
absence of a parent or father’s approval, including domestic
violence, mothers or grandparents being blamed for a child’s
death, and households being split [18]. In situations with strongly
inequitable power relations such as vulnerable clinical contexts
[23], mothers also sometimes request to wait for their husbands as
a way of ‘silently refusing’; as a way of exercising their own agency
[24]. Although fears and concerns leading to silent refusals might
be related more to a community or an individual’s lack of trust in
research or in the research staff, rather than to issues specific to a
trial, an ability to refuse is a right, even if it is based on apparently
‘irrational’ argument [1].
The challenge with accepting all deferrals of research decisions
to fathers in settings like Soroti and especially Kilifi is that the
majority of mothers bring their children to hospital without their
husbands. It may also be that many fathers would regret their
wives not having agreed to studies when they are later informed,
particularly given that most trials have a positive impact on all
participants – the trial effect – regardless of which arm they are in;
a positive impact which was noted in the FEAST trial, and also
[25] perceived by parents of FEAST trial participants, particularly
in Soroti. Another challenge is the cost and size of studies and the
potential to introduce bias, if all mothers wanting to wait for
husbands is strongly adhered to. At this stage, without further
information, it is difficult to justify not allowing mothers to wait for
their husbands or for relatives to wait for parents; an approach
which appeared to contribute to relatively high refusal rates in
Kilifi. To argue otherwise would be to weigh cost against very real
risks to mothers, and their ability to exercise choice; i.e. the moral
goal of consent [26].
What does assent mean in the deferred consent
process?. Beyond the issues raised above about who can assent,
Kilifi staff in particular raised a concern about whether an
affirmative ‘yes’ was needed from those providing the assent. With
most parents overwhelmed and distressed by their child’s
condition on arrival, ascertaining a positive response from some
parents was difficult. Some staff felt that it was essential to have a
clear go ahead while others felt that this should not be mandatory
because it introduces additional unnecessary pressures and delays.
One potential option moving forwards would be to consider the
assent process as an opt out opportunity, where those who are
generally opposed to any research can refuse, either openly or
through the silent approaches noted above, regardless of their
reasons. Here there would an acceptance of some loss of
voluntariness in order to minimise the risks and distress associated
with taking time to give a definitive response. A related challenge is
the precise assent information that is given, and in particular how
to distinguish between usual clinical care and interventions or
procedures specific to clinical research in a way that is brief but
clear. Clinical research, clinical care and quality improvement
overlap so much that decisions are potentially rendered meaning-
less.
Should parents be consented retrospectively after the
death of their child?. Current recommendations require that
the relatives or guardians of a research subject entered into a
clinical investigation with waived consent be informed of their
participation even after death (21CFR50.24). The FEAST trial did
not do this, for similar reasons to others. For example Jansen et al
(2007) noted:
‘Confronting relatives again with the event that their loved one died on
the ICU can be seen as harm or burden… If we can say that
confronting bereaved relatives represents additional burden, which we
have the duty [as providers] to relieve or prevent, it seems morally correct
to adopt policies that prevent seeking deferred consent from proxy’s after
their relatives’ death’ (p897).
Shilling and Young (2009) also showed that parents feared
making a ‘wrong decision’ and living with the knowledge that the
‘wrong decision’ led to a poor outcome. In retrospect, this might
have particularly applied to parents of children in the FEAST trial,
given the unexpected negative findings, although as noted above
there is a strong suggestion that there was a positive trial effect on
all participating children. Our interviews with staff members
suggest that choosing not to proceed with the full consent process
after the death of a child was appropriate, humane and
appreciated. However, we did not interview parents of children
who had died, and there were some staff members who were
concerned that parents should be informed primarily for legal
protection reasons. Although staff could potentially be reassured
about the legal issues, a challenge with not fully informing parents
is the possibility in the longer term of parents perceiving that full
information had been concealed from them, with potentially
negative implications for trust and future research [13].
Do parents have a choice?. A particularly fundamental
concern with meeting the moral commitment of consent is that of
parents being so desperate or vulnerable that they feel ‘they have
no choice’. Where this choice is based on an obvious disparity
between the standard of care or costs for participants and non-
participants, as was apparently more the case in Soroti, this raises
potential concerns about undue inducement [27], and suggests the
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need for mechanisms to strengthen equity across participants and
non-participants. This could be through for example increasing
benefits that go to all ward patients as opposed to just participants;
an approach aimed at fair benefits [28,29]. However, this would in
turn raise concerns about costs of such trials given the significant
resource constraints in many hospitals, and the generalisability of
findings to settings beyond the trial sites. Indirect benefits to all
patients, such as on-site training for all hospital staff, professional
development and general improvement of the organisation of
emergency care are relatively realistic, but do not entirely remove
inequities and this concern.
Activities to Support Strengthened Consent Processes
Good training and consent support processes are clearly
essential for staff involved in emergency trials, with an important
set of communications skills required including being able to read
and respond to the variability among parents (in terms of their
mood, understanding and information needs at a given time), and
being able to recognise silent agreements or refusals. The FEAST
trial training and supportive supervision processes, including for
consent, were greatly appreciated by staff, and are essential in all
research settings given that frontline staff are constantly making
ethically important decisions [14,30]. Our data suggests that
supportive supervision needs to be constant, and to be seeking out
and responding continuously to challenges and areas lacking
clarity as they arise. This support should continue after a trial is
ended, possibly especially where there are unexpected findings:
however carefully, equipoise has been explained in initial protocols
and trainings, frontline staff may develop their own expectations
and interpretations. Our data also suggest that consent training
should include discussion and debate on ethical and moral
approaches to consent, including: 1) national and international
review processes, including why and how alternatives to full prior
consent are approved, and how staff are legally protected; and 2)
how best to ensure that on a day-to-day basis, the legal elements
and requirements of a trial do not outweigh the moral [31].
Conclusion
The overall approach of using a deferred consent process with a
prior assent was generally supported, particularly by trial clinicians
and nurses. Prior assent was seen as protecting the interests of both
patients and researchers, including through minimising delays in
starting treatment. The potential challenges were voluntariness
being undermined through inadequate assent information being
poorly understood, and any information giving on admission
acting as a form of harm or disadvantage through causing real or
perceived delays. Further challenges raised included what to do in
the absence of a father, and what it means and what to do when
mothers do not give a clear agreement or refusal. While these
challenges are faced in all studies, they are magnified by the
urgency of the situation, and the need to make rapid decisions.
Possible ways forward for consent for paediatric emergency
research depend on the level of risk of a study, and on the context.
For a minimal risk study a consent waiver or retrospective consent
may be considered appropriate. For a non-minimal risk study like
FEAST, one possible option is prior assent for all parents, with an
option for full prior consent given as part of the assent information.
This approach would consider assent essentially as an opt-out
mechanism, whereby some loss of voluntariness is accepted in
order to minimise the risks and distress associated with taking time
to give a definitive response.
Regardless of the approach adopted, the importance of strong
communication skills and support for all frontline staff, and their
understanding of the moral bases for consent, and of the science
and ethics review process and of the legal protections they have, is
clear. Nevertheless, concrete decisions on ways forwards requires
further discussion and reflection, including through consultation
with staff members and community representatives, including
men, using a deliberative approach.
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